Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity

被引：12
|
作者：
Koehler, M. [1 ]
Donnelly, E. T. [2 ]
Kalanovic, D. [3 ]
Dagher, R. [4 ]
Rothenberg, M. L. [1 ]
机构：
[1] Pfizer Oncol, New York, NY 10017 USA
[2] Pfizer Oncol, Cambridge, MA USA
[3] Pfizer Oncol, Reg Med Affairs, Berlin, Germany
[4] Pfizer, Worldwide Safety & Regulatory, Groton, CT USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 07期
关键词：
WORLD EFFECTIVENESS TRIAL; MULTIPLE-MYELOMA; DRUG DEVELOPMENT; SALFORD LUNG; BORTEZOMIB; PROTOCOL; AGE;
D O I：
10.1093/annonc/mdw143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We propose that for oncology drugs that demonstrate "exceptional activity" in Phase 1 or Phase 2 trials and receive accelerated/conditional approval and/or Breakthrough Therapy Designation, and for certain expanded indications, regulatory authorities should consider accepting data from prospectively-agreed pragmatic randomized clinical trials to grant full regulatory approval.
引用
收藏
页码：1342 / 1348
页数：7
相关论文
共 50 条
  • [1] Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement
    Hohenschurz-Schmidt, David
    Cherkin, Dan
    Rice, Andrew S. C.
    Dworkin, Robert H.
    Turk, Dennis C.
    Mcdermott, Michael P.
    Bair, Matthew J.
    Debar, Lynn L.
    Edwards, Robert R.
    Evans, Scott R.
    Farrar, John T.
    Kerns, Robert D.
    Rowbotham, Michael C.
    Wasan, Ajay D.
    Cowan, Penney
    Ferguson, Mckenzie
    Freeman, Roy
    Gewandter, Jennifer S.
    Gilron, Ian
    Grol-Prokopczyk, Hanna
    Iyengar, Smriti
    Kamp, Cornelia
    Karp, Barbara I.
    Kleykamp, Bethea A.
    Loeser, John D.
    Mackey, Sean
    Malamut, Richard
    Mcnicol, Ewan
    Patel, Kushang V.
    Schmader, Kenneth
    Simon, Lee
    Steiner, Deborah J.
    Veasley, Christin
    Vollert, Jan
    PAIN, 2024, 165 (10) : 2165 - 2183
  • [2] Genetically directed therapies for cancer in early clinical trials
    McNamee, D
    LANCET, 1997, 349 (9065): : 1605 - 1605
  • [3] Preliminary data release for randomized clinical trials of noninferiority: A new proposal
    Korn, EL
    Hunsberger, S
    Freidlin, B
    Smith, MA
    Abrams, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5831 - 5836
  • [4] PROPOSAL FOR A NEW SECTION IN LUNG-CANCER ON ONGOING RANDOMIZED TRIALS
    PIGNON, JP
    ARRIAGADA, R
    LUNG CANCER, 1994, 11 (5-6) : 401 - 403
  • [5] Evaluation of the clinical utility of new diagnostic tests for tuberculosis: the role of pragmatic clinical trials
    Huf, Gisele
    Kritski, Afranio
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2012, 38 (02) : 237 - 245
  • [6] THE CLINICAL IMPORTANCE OF EARLY STOPPING OF RANDOMIZED TRIALS IN CANCER TREATMENTS
    SOUHAMI, RL
    STATISTICS IN MEDICINE, 1994, 13 (13-14) : 1293 - 1295
  • [7] Randomized designs for early trials of new cancer treatments - An overview
    Buyse, M
    DRUG INFORMATION JOURNAL, 2000, 34 (02): : 387 - 396
  • [8] Randomized Designs for Early Trials of New Cancer Treatments—An Overview
    Marc Buyse
    Drug information journal : DIJ / Drug Information Association, 2000, 34 (2): : 387 - 396
  • [9] Evaluation of epigenetic therapies in early clinical trials: Development of novel pharmacodynamic endpoints.
    Fernie, NL
    Plumb, JA
    Atadja, P
    Remiszewski, S
    Brown, R
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6257S - 6257S
  • [10] Evaluation of the study of control arms in randomized clinical trials of cancer.
    Jain, Sandeep Kumar
    Zauderer, Marjorie Glass
    Sethi, Tarsheen
    Schoen, Martin W.
    Rubinstein, Sam
    Nguyen, Ryan Huu-Tuan
    Nagpal, Seema
    Mohan, Sanjay
    Madireddy, Sathwik
    Lythgoe, Mark
    Liang, Wayne
    Kulkarni, Amit
    Kothari, Shalin
    Hilal, Talal
    Hadfield, Matthew James
    Goyal, Gaurav
    Ganta, Teja
    Dholaria, Bhagirathbhai R.
    Brown, Alaina J.
    Warner, Jeremy Lyle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345